A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT05619692 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild Cognitive Impairment
Mild Dementia
Alzheimer's Disease

Interventions

DRUG: SAGE-718
DRUG: SAGE-718-matching Placebo

Sponsor

Supernus Pharmaceuticals, Inc.